Isocitrate dehydrogenase 3 alpha (IDH3A) is a critical mitochondrial enzyme in the tricarboxylic acid (TCA) cycle that plays a pivotal role in cellular energy metabolism. This gene has garnered significant attention in neurodegeneration research due to its essential function in neuronal ATP production and its involvement in multiple neurodegenerative disease pathways. IDH3A catalyzes the rate-limiting oxidative decarboxylation step in the TCA cycle, converting isocitrate to α-ketoglutarate (α-KG) while generating NADH for the electron transport chain. Recent research has revealed that IDH3A dysfunction contributes to the metabolic deficits observed in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders [1][2].
| Property | Value |
|---|---|
| Gene Symbol | IDH3A |
| Full Name | Isocitrate Dehydrogenase 3 Alpha |
| Chromosomal Location | 7q32.2 |
| Protein Length | 413 amino acids |
| Molecular Weight | ~46 kDa |
| Subcellular Localization | Mitochondrial matrix |
| Enzyme Classification | EC 1.1.1.41 (NAD+-dependent) |
IDH3A is a NAD+-dependent isocitrate dehydrogenase that functions as a heterotetramer composed of α, β, and γ subunits. Unlike its paralogs IDH1 (cytosolic, NADP+-dependent) and IDH2 (mitochondrial, NADP+-dependent), IDH3A uses NAD+ as its cofactor, making it uniquely positioned to couple TCA cycle activity with cellular NAD+ homeostasis. The enzyme undergoes allosteric regulation by adenine nucleotides: ADP activates while ATP and NADH inhibit its activity. Calcium ions serve as an additional activator, linking enzyme activity to neuronal calcium signaling [1][2].
IDH3A catalyzes the rate-limiting oxidative decarboxylation reaction:
Isocitrate + NAD+ + Mg2+ → α-Ketoglutarate + NADH + CO2 + H+
This reaction is:
In neurons, IDH3A is critically important because:
The enzyme is regulated by:
Metabolic dysfunction is a hallmark of AD, with multiple studies documenting reduced TCA cycle enzyme activity in AD brain tissue. IDH3A activity is diminished in hippocampal and cortical regions of AD patients, contributing to:
Mitochondrial dysfunction is central to PD pathogenesis. IDH3A contributes to PD through:
IDH3A mutations cause autosomal recessive Leigh syndrome, characterized by:
IDH3A mutations cause autosomal dominant retinitis pigmentosa, affecting:
Multiple therapeutic approaches target IDH3A-related pathways:
IDH3A-adjacent targets include:
IDH3A expression across tissues:
In the brain, IDH3A is expressed in:
| Year | Discovery |
|---|---|
| 1970s | IDH3A enzyme characterized |
| 1990s | Gene cloned and mapped to 7q32 |
| 2000s | Mutations linked to RP |
| 2010s | Role in neurodegeneration established |
| 2020s | Metabolic therapies in trials |